Hatcher, Simon http://orcid.org/0000-0003-3117-2350
Heisel, Marnin J.
Ayonrinde, Oydeji
Corsi, Daniel
Edgar, Nicole E.
Kennedy, Sidney H.
Rizvi, Sakina J.
Schaffer, Ayal
Sinyor, Mark
Funding for this research was provided by:
Ontario SPOR Support Unit
Article History
Received: 19 July 2022
Accepted: 25 September 2022
First Online: 5 October 2022
Declarations
:
: This protocol has received research ethics board (REB) approval from the OHSN-REB as the board of record via Clinical Trials Ontario (CTO reference CTO-790). All active study sites have received approval.
: Not applicable.
: The study investigators have the following competing interests to declare: SJR is a coinvestigator with the Canadian Biomarker Integration Network in Depression (CAN-BIND), funded by the Ontario Brain Institute (OBI). She also received research grant funding from Pfizer Canada. The other authors declare that they have no competing interests. Dr. Sidney H. Kennedy has received funding for Consulting or Speaking engagements from Abbvie, Boehringer-Ingelheim, Janssen, Lundbeck, Lundbeck Institute, Merck, Otsuka Pfizer, Sunovion, and Servier. He has received Research Support from Abbott, Brain Canada, CIHR (Canadian Institutes of Health Research), Janssen, Lundbeck, Ontario Brain Institute, Otsuka, Pfizer, and SPOR (Canada’s Strategy for Patient-Oriented Research). He has stock/stock options in Field Trip Health.